본문 바로가기
KERD
논문KCI 등재

Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives

김혜련|임선민|Min Hee Hong
대한면역학회 (The Korean Association of Immunologists)|2020.02|Immune Network|제20권 제1호|pp. 1-14|DOI 10.4110/in.2020.20.e10

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

ImmunotherapyNon-small cell lung cancerProgrammed cell death protein 1

초록

Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective treatment option even in the first-line setting. ICIs can block inhibitory pathways that restrain the immune response against cancer, restoring and sustaining antitumor immunity. Currently, there are 4 PD-1/PD-L1 blocking agents available in clinics, and immunotherapy-based regimen alone or in combination with chemotherapy is now preferred option. Combination trials assessing combination of ICIs with chemotherapy, targeted therapy and other immunotherapy are ongoing. Controversies remain regarding the use of ICIs in targetable oncogene-addicted subpopulations, but their initial treatment recommendations remained unchanged, with specific tyrosine kinase inhibitors as the choice. For the majority of patients without targetable driver oncogenes, deciding between therapeutic options can be difficult due to lack of direct cross-comparison studies. There are continuous efforts to find predictive biomarkers to find those who respond better to ICIs. PD-L1 protein expressions by immunohistochemistry and tumor mutational burden have emerged as most well-validated biomarkers in multiple clinical trials. However, there still is a need to improve patient selection, and to establish the most effective concurrent or sequential combination therapies in different NSCLC clinical settings. In this review, we will introduce currently used ICIs in NSCLC and analyze most recent trials, and finally discuss how, when and for whom ICIs can be used to provide promising avenues for lung cancer treatment.

Abstract

Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective treatment option even in the first-line setting. ICIs can block inhibitory pathways that restrain the immune response against cancer, restoring and sustaining antitumor immunity. Currently, there are 4 PD-1/PD-L1 blocking agents available in clinics, and immunotherapy-based regimen alone or in combination with chemotherapy is now preferred option. Combination trials assessing combination of ICIs with chemotherapy, targeted therapy and other immunotherapy are ongoing. Controversies remain regarding the use of ICIs in targetable oncogene-addicted subpopulations, but their initial treatment recommendations remained unchanged, with specific tyrosine kinase inhibitors as the choice. For the majority of patients without targetable driver oncogenes, deciding between therapeutic options can be difficult due to lack of direct cross-comparison studies. There are continuous efforts to find predictive biomarkers to find those who respond better to ICIs. PD-L1 protein expressions by immunohistochemistry and tumor mutational burden have emerged as most well-validated biomarkers in multiple clinical trials. However, there still is a need to improve patient selection, and to establish the most effective concurrent or sequential combination therapies in different NSCLC clinical settings. In this review, we will introduce currently used ICIs in NSCLC and analyze most recent trials, and finally discuss how, when and for whom ICIs can be used to provide promising avenues for lung cancer treatment.

참고문헌 (54)

  1. Borghaei H, "Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer", N Engl J Med, 373, pp.1627~1639 (2015)
  2. Herbst RS, "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010) : a randomised controlled trial", Lancet, 387, pp.1540~1550 (2016)
  3. Rittmeyer A, "Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer(OAK) : a phase 3, open-label, multicentre randomised controlled trial", Lancet, 389, pp.255~265 (2017)
  4. Antonia SJ, "Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC", N Engl J Med, 379, pp.2342~2350 (2018)
  5. Faruki H, "Lung adenocarcinoma and squamous cell carcinoma gene expression subtypes demonstrate significant differences in tumor immune landscape", J Thorac Oncol, 12, pp.943~953 (2017)
  6. Seo JS, "Comprehensive analysis of the tumor immune micro-environment in non-small cell lung cancer for efficacy of checkpoint inhibitor", Sci Rep, 8, pp.14576~ (2018)
  7. Anichini A, "The non-small cell lung cancer immune landscape : emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy", Cancer Immunol Immunother, 67, pp.1011~1022 (2018)
  8. Reck M, "Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer", N Engl J Med, 375, pp.1823~1833 (2016)
  9. Taube JM, "Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy", Clin Cancer Res, 20, pp.5064~5074 (2014)
  10. Mehnert JM, "The challenge for development of valuable immuno-oncology biomarkers", Clin Cancer Res, 23, pp.4970~4979 (2017)
  11. Rizvi NA, "Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer", Science, 348, pp.124~128 (2015)
  12. Peters S, "Abstract ct082 : Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage IV or recurrent non-small cell lung cancer : an exploratory analysis of checkmate 026", Cancer Res, 77, pp.CT082~ (2017)
  13. Ramalingam SS, "Abstract ct078 : Tumor mutational burden(tmb)as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab(nivo)+ ipilimumab(ipi)in first-line(1l)non-small cell lung cancer(nsclc) : Identification of tmb cutoff from checkmate 568", Cancer Res, 78, pp.CT078~ (2018)
  14. Hellmann MD, "Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden", N Engl J Med, 378, pp.2093~2104 (2018)
  15. Felip Font E, "Three-year follow-up from checkmate 017", 057 : Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer(NSCLC), 2017, ~
  16. Brahmer J, "Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer", N Engl J Med, 373, pp.123~135 (2015)
  17. Büttner R, "Programmed death-ligand 1 immunohistochemistry testing : a review of analytical assays and clinical implementation in non-small-cell lung cancer", J Clin Oncol, 35, pp.3867~3876 (2017)
  18. Tsao MS, "PD-L1 immunohistochemistry comparability study in real-life clinical samples : results of blueprint phase 2 project", J Thorac Oncol, 13, pp.1302~1311 (2018)
  19. Lopes GW, "Pembrolizumab versus platinum-based chemotherapy as first-line therapy for advanced", metastatic nsclc with a PD-L1 tumor proportion score >=1% : open-label, phase 3 keynote-042 study, 2018, pp.36, 36~
  20. Carbone DP, "First-line nivolumab in stage IV or recurrent non-small-cell lung cancer", N Engl J Med, 376, pp.2415~2426 (2017)
  21. Rizvi NA, "Lba6durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer : mystic", Ann Oncol, 29(Suppl 10), pp.mdy511.005~ (2018)
  22. Bracci L, "Immune-based mechanisms of cytotoxic chemotherapy : implications for the design of novel and rationale-based combined treatments against cancer", Cell Death Differ, 21, pp.15~25 (2014)
  23. Zitvogel L, "Mechanism of action of conventional and targeted anticancer therapies : reinstating immunosurveillance", Immunity, 39, pp.74~88 (2013)
  24. Roselli M, "Effects of conventional therapeutic interventions on the number and function of regulatory T cells", OncoImmunology, 2, pp.e27025~ (2013)
  25. Wang Z, "Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells", OncoImmunology, 6, pp.e1331807~ (2017)
  26. Gandhi L, "Pembrolizumab plus chemotherapy in lung cancer", N Engl J Med, 379, pp.e18~ (2018)
  27. "NCCN clinical practice guidelines in oncology. Non-small cell lung cancer"[URL]
  28. Socinski MA, "Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC", N Engl J Med, 378, pp.2288~2301 (2018)
  29. Papadimitrakopoulou VA, "Impower132: PFS and safety results with 1l atezolizumab + carboplatin", cisplatin + pemetrexed in stage IV non-squamous NSCLC, 2018, ~[DOI]
  30. Paz-Ares L, "Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer", N Engl J Med, 379, pp.2040~2051 (2018)
  31. Jotte RM, "Impower131 : primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC", J Clin Oncol, 36, pp.LBA9000~ (2018)
  32. "Bristol-Myers Squibb to announce results for fourth quarter 2018 on January 24"[URL]
  33. Ready N, "First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer(checkmate 568) : outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers", J Clin Oncol, 37, pp.992~1000 (2019)
  34. Papadopoulos KP, "First-in-human study of REGN3767(R3767), a human LAG-3 monoclonal antibody(mAb), ± cemiplimab in patients(pts)with advanced malignancies", J Clin Oncol, 37, pp.2508~ (2019)
  35. Mølhøj M, "CD19-", CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis, 2007, pp.44, 1935~1943
  36. Rosenberg SA, "Cancer immunotherapy : moving beyond current vaccines", Nat Med, 10, pp.909~915 (2004)
  37. Meric-Bernstam F, "Phase ib study of miw815(ADU-S100)in combination with spartalizumab(PDR001)in patients(pts)with advanced", metastatic solid tumors or lymphomas, 2019, pp.37, 2507~
  38. Ahn MJ, "136o : osimertinib combined with durvalumab in egfr-mutant non-small cell lung cancer : results from the tatton phase ib trial", J Thorac Oncol, 11, pp.S115~ (2016)
  39. Kim DW, "Safety and clinical activity results from a phase ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC(aNSCLC)", J Clin Oncol, 36, pp.9009~ (2018)
  40. Lisberg A, "A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC", J Thorac Oncol, 13, pp.1138~1145 (2018)
  41. Allard B, "Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs", Clin Cancer Res, 19, pp.5626~5635 (2013)
  42. Gandara DR, "Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab", Nat Med, 24, pp.1441~1448 (2018)
  43. Kim ES, "Primary efficacy results from b-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)", Ann Oncol, 29(Suppl 8), pp.29~ (2018)
  44. Postow MA, "Immune-related adverse events associated with immune checkpoint blockade", N Engl J Med, 378, pp.158~168 (2018)
  45. Das S, "Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors", J Immunother Cancer, 7, pp.306~ (2019)
  46. Haratani K, "Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer", JAMA Oncol, 4, pp.374~378 (2018)
  47. Teraoka S, "Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab : a prospective cohort study", J Thorac Oncol, 12, pp.1798~1805 (2017)
  48. Puzanov I, "Managing toxicities associated with immune checkpoint inhibitors : consensus recommendations from the Society for Immunotherapy of Cancer(SITC)Toxicity Management Working Group", J Immunother Cancer, 5, pp.95~ (2017)
  49. Brahmer JR, "Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy : American Society of Clinical Oncology Clinical Practice Guideline", J Clin Oncol, 36, pp.1714~1768 (2018)
  50. Champiat S, "Management of immune checkpoint blockade dysimmune toxicities : a collaborative position paper", Ann Oncol, 27, pp.559~574 (2016)
  51. Robert C, "Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma", J Clin Oncol, 36, pp.1668~1674 (2018)
  52. Kim JY, "Hyperprogressive disease during anti-PD-1 (PDCD1)", PD-L1 (CD274) therapy: a systematic review and meta-analysis, 2019, pp.11, 11~
  53. Kato S, "Hyperprogressors after immunotherapy : analysis of genomic alterations associated with accelerated growth rate", Clin Cancer Res, 23, pp.4242~4250 (2017)
  54. Kim CG, "Hyperprogressive disease during PD-1", PD-L1 blockade in patients with non-small-cell lung cancer, 2019, pp.30, 1104~1113

관련 논문AI추천

Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer안명주, 임성원대한내과학회 · The Korean Journal of Internal Medicine2019 · 제34권 제1호Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles조주환대한면역학회 · Immune Network2017 · 제17권 제6호Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerationsJae Kyeom Sim, Juwhan Choi, Sung Yong Lee대한내과학회 · The Korean Journal of Internal Medicine2023 · 제38권 제6호PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future김효진, 정진행대한병리학회 · Journal of Pathology and Translational Medicine2019 · 제53권 제4호An update on immunotherapy with PD-1 and PD-L1 blockade고성애영남대학교 의과대학 · Journal of Yeungnam Medical Science2021 · 제38권 제4호Updates to Clinical Information on Anticancer Immunotherapy양재욱, 최은주한국임상약학회 · 한국임상약학회지2018 · 제28권 제1호

이 간행물의 다른 논문 (10건)

Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors이승룡, Juwhan Choipp. 1-21Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?박준용, Hye Won Lee, Kyung Joo Chopp. 1-14Re-defining T-Cell Exhaustion: Subset, Function, and Regulation하상준, Se Jin Impp. 1-19Coalition Forces of Immunologists and Oncologists for Defeating Cancer신의철, Deputy Editor, Immune Networkpp. 1-2Peripheral Blood Immune Cell-based Biomarkers in Anti-PD-1/PD-L1 Therapy신의철, 김경환, Chang Gon Kimpp. 1-15
원문 보기